{"entity":{"type":"insider","cik":"0001838047","url":"/insider/0001838047","json_url":"/insider/0001838047.json","name":"Uger Robert","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":12,"n_filings":10,"first":"2021-01-11","last":"2021-07-09","span_basis":"filed_date"},"name_variants":[{"name":"Uger Robert","source":"filing","n_filings":10,"first_seen":"2021-01-11","last_seen":"2021-07-09"}],"transactions":[{"id":4874563,"accession":"0001062993-21-006419","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-21-006419","line_url":"/filing/0001062993-21-006419#line-2","is_derivative":false,"issuer_cik":"0001616212","issuer_name":"Trillium Therapeutics Inc.","issuer_ticker":"TRIL","issuer_name_source":null,"issuer_url":"/issuer/0001616212","owner_cik":"0001838047","owner_name":"Uger Robert","owner_url":"/insider/0001838047","role":"Officer (Chief Scientific Officer)","officer_title":"Chief Scientific Officer","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3646.0,"shares_display":"3,646","price_per_share":9.0,"price_display":"9.00","price_state":"stated","total_value":32814.0,"total_display":"32,814.00","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-07-07","filed_date":"2021-07-09","scope":"insider"},{"id":4985958,"accession":"0001062993-21-005487","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-21-005487","line_url":"/filing/0001062993-21-005487#line-2","is_derivative":false,"issuer_cik":"0001616212","issuer_name":"Trillium Therapeutics Inc.","issuer_ticker":"TRIL","issuer_name_source":null,"issuer_url":"/issuer/0001616212","owner_cik":"0001838047","owner_name":"Uger Robert","owner_url":"/insider/0001838047","role":"Officer (Chief Scientific Officer)","officer_title":"Chief Scientific Officer","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3646.0,"shares_display":"3,646","price_per_share":8.27,"price_display":"8.27","price_state":"stated","total_value":30152.42,"total_display":"30,152.42","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-07","filed_date":"2021-06-09","scope":"insider"},{"id":4364162,"accession":"0001062993-21-004390","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-21-004390","line_url":"/filing/0001062993-21-004390#line-2","is_derivative":false,"issuer_cik":"0001616212","issuer_name":"Trillium Therapeutics Inc.","issuer_ticker":"TRIL","issuer_name_source":null,"issuer_url":"/issuer/0001616212","owner_cik":"0001838047","owner_name":"Uger Robert","owner_url":"/insider/0001838047","role":"Officer (Chief Scientific Officer)","officer_title":"Chief Scientific Officer","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3646.0,"shares_display":"3,646","price_per_share":9.3,"price_display":"9.30","price_state":"stated","total_value":33907.8,"total_display":"33,907.80","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-07","filed_date":"2021-05-11","scope":"insider"},{"id":4614905,"accession":"0001062993-21-003543","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-21-003543","line_url":"/filing/0001062993-21-003543#line-2","is_derivative":false,"issuer_cik":"0001616212","issuer_name":"Trillium Therapeutics Inc.","issuer_ticker":"TRIL","issuer_name_source":null,"issuer_url":"/issuer/0001616212","owner_cik":"0001838047","owner_name":"Uger Robert","owner_url":"/insider/0001838047","role":"Officer (Chief Scientific Officer)","officer_title":"Chief Scientific Officer","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3646.0,"shares_display":"3,646","price_per_share":10.82,"price_display":"10.82","price_state":"stated","total_value":39449.72,"total_display":"39,449.72","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-07","filed_date":"2021-04-09","scope":"insider"},{"id":4455892,"accession":"0001062993-21-002721","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-21-002721","line_url":"/filing/0001062993-21-002721#line-2","is_derivative":false,"issuer_cik":"0001616212","issuer_name":"Trillium Therapeutics Inc.","issuer_ticker":"TRIL","issuer_name_source":null,"issuer_url":"/issuer/0001616212","owner_cik":"0001838047","owner_name":"Uger Robert","owner_url":"/insider/0001838047","role":"Officer (Chief Scientific Officer)","officer_title":"Chief Scientific Officer","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2917.0,"shares_display":"2,917","price_per_share":11.97,"price_display":"11.97","price_state":"stated","total_value":34916.49,"total_display":"34,916.49","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-12","filed_date":"2021-03-15","scope":"insider"},{"id":5094557,"accession":"0001062993-21-002588","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-21-002588","line_url":"/filing/0001062993-21-002588#line-2","is_derivative":false,"issuer_cik":"0001616212","issuer_name":"Trillium Therapeutics Inc.","issuer_ticker":"TRIL","issuer_name_source":null,"issuer_url":"/issuer/0001616212","owner_cik":"0001838047","owner_name":"Uger Robert","owner_url":"/insider/0001838047","role":"Officer (Chief Scientific Officer)","officer_title":"Chief Scientific Officer","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3646.0,"shares_display":"3,646","price_per_share":10.11,"price_display":"10.11","price_state":"stated","total_value":36861.06,"total_display":"36,861.06","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-08","filed_date":"2021-03-10","scope":"insider"},{"id":5528722,"accession":"0001062993-21-001198","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001062993-21-001198","line_url":"/filing/0001062993-21-001198#line-5","is_derivative":false,"issuer_cik":"0001616212","issuer_name":"Trillium Therapeutics Inc.","issuer_ticker":"TRIL","issuer_name_source":null,"issuer_url":"/issuer/0001616212","owner_cik":"0001838047","owner_name":"Uger Robert","owner_url":"/insider/0001838047","role":"Officer (Chief Scientific Officer)","officer_title":"Chief Scientific Officer","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":584.0,"shares_display":"584","price_per_share":14.124,"price_display":"14.12","price_state":"stated","total_value":8248.416,"total_display":"8,248.42","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-09","filed_date":"2021-02-10","scope":"insider"},{"id":5528717,"accession":"0001062993-21-001198","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001062993-21-001198","line_url":"/filing/0001062993-21-001198#line-3","is_derivative":false,"issuer_cik":"0001616212","issuer_name":"Trillium Therapeutics Inc.","issuer_ticker":"TRIL","issuer_name_source":null,"issuer_url":"/issuer/0001616212","owner_cik":"0001838047","owner_name":"Uger Robert","owner_url":"/insider/0001838047","role":"Officer (Chief Scientific Officer)","officer_title":"Chief Scientific Officer","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6563.0,"shares_display":"6,563","price_per_share":12.65,"price_display":"12.65","price_state":"stated","total_value":83021.95,"total_display":"83,021.95","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-08","filed_date":"2021-02-10","scope":"insider"},{"id":4513396,"accession":"0001062993-21-000340","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-21-000340","line_url":"/filing/0001062993-21-000340#line-2","is_derivative":false,"issuer_cik":"0001616212","issuer_name":"Trillium Therapeutics Inc.","issuer_ticker":"TRIL","issuer_name_source":null,"issuer_url":"/issuer/0001616212","owner_cik":"0001838047","owner_name":"Uger Robert","owner_url":"/insider/0001838047","role":"Officer (Chief Scientific Officer)","officer_title":"Chief Scientific Officer","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":584.0,"shares_display":"584","price_per_share":15.2032,"price_display":"15.20","price_state":"stated","total_value":8878.6688,"total_display":"8,878.67","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-11","filed_date":"2021-01-13","scope":"insider"},{"id":5198506,"accession":"0001062993-21-000291","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001062993-21-000291","line_url":"/filing/0001062993-21-000291#line-4","is_derivative":false,"issuer_cik":"0001616212","issuer_name":"Trillium Therapeutics Inc.","issuer_ticker":"TRIL","issuer_name_source":null,"issuer_url":"/issuer/0001616212","owner_cik":"0001838047","owner_name":"Uger Robert","owner_url":"/insider/0001838047","role":"Officer (Chief Scientific Officer)","officer_title":"Chief Scientific Officer","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5600.0,"shares_display":"5,600","price_per_share":15.817,"price_display":"15.82","price_state":"stated","total_value":88575.2,"total_display":"88,575.20","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-08","filed_date":"2021-01-12","scope":"insider"},{"id":5198501,"accession":"0001062993-21-000291","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001062993-21-000291","line_url":"/filing/0001062993-21-000291#line-3","is_derivative":false,"issuer_cik":"0001616212","issuer_name":"Trillium Therapeutics Inc.","issuer_ticker":"TRIL","issuer_name_source":null,"issuer_url":"/issuer/0001616212","owner_cik":"0001838047","owner_name":"Uger Robert","owner_url":"/insider/0001838047","role":"Officer (Chief Scientific Officer)","officer_title":"Chief Scientific Officer","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2917.0,"shares_display":"2,917","price_per_share":15.5058,"price_display":"15.51","price_state":"stated","total_value":45230.4186,"total_display":"45,230.42","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-08","filed_date":"2021-01-12","scope":"insider"},{"id":4209176,"accession":"0001062993-21-000263","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001062993-21-000263","line_url":"/filing/0001062993-21-000263#line-2","is_derivative":false,"issuer_cik":"0001616212","issuer_name":"Trillium Therapeutics Inc.","issuer_ticker":"TRIL","issuer_name_source":null,"issuer_url":"/issuer/0001616212","owner_cik":"0001838047","owner_name":"Uger Robert","owner_url":"/insider/0001838047","role":"Officer (Chief Scientific Officer)","officer_title":"Chief Scientific Officer","security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3646.0,"shares_display":"3,646","price_per_share":14.751,"price_display":"14.75","price_state":"stated","total_value":53782.146,"total_display":"53,782.15","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-07","filed_date":"2021-01-11","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":12,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":12,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":12},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001616212","name":"Trillium Therapeutics Inc.","url":"/issuer/0001616212","role":"Officer (Chief Scientific Officer)","n_filings":10,"first_seen":"2021-01-11","last_seen":"2021-07-09"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001838047","retrieved_at":"2026-08-22T03:05:15+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}